Researchers at Daiichi Sankyo Co. Ltd. Report Research in Multiple Myeloma (A novel T cell-redirecting anti-GPRC5D CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models).

A recent report from Daiichi Sankyo Co. Ltd. discusses research on multiple myeloma, a type of blood cancer. The researchers developed a novel bispecific antibody called BsAb5003 that targets a protein called GPRC5D, which is found in malignant plasma cells in 90% of multiple myeloma patients. The antibody showed promising results in preclinical models, inducing cytotoxicity of GPRC5D-positive cancer cells and activating T cells. The researchers suggest that BsAb5003 could be an effective treatment for a wide range of multiple myeloma patients, either as a monotherapy or in combination with other drugs. [Extracted from the article]